Table 5.
Clinical outcome of patients with different BME change
| Before ESWT | Final follow-up | P value | |
|---|---|---|---|
| Harris hip score | |||
| BME improved | |||
| Total | 77.8 ± 15.6 | 89.7 ± 11.1 | < 0.001 |
| ARCO stage I | 84.6 ± 15.4 | 95.6 ± 4.5 | 0.175 |
| ARCO stage II | 80.5 ± 14.3 | 91.1 ± 11.0 | 0.006 |
| ARCO stage III | 60.4 ± 8.5 | 78.0 ± 9.1 | 0.045 |
| BME unchanged | |||
| Total | 77.2 ± 15.1 | 79.8 ± 17.2 | 0.354 |
| ARCO stage I | 85.3 ± 8.1 | 98.3 ± 9.1 | 0.157 |
| ARCO stage II | 81.4 ± 14.5 | 81.6 ± 12.8 | 0.970 |
| ARCO stage III | 59.0 ± 3.5 | 57.3 ± 1.2 | 0.560 |
| BME progressed | |||
| Total | 67.0 | 96.0 | / |
| ARCO stage II | 67.0 | 96.0 | / |
| VAS | |||
| BME improved | |||
| Total | 3.8 ± 2.8 | 1.6 ± 1.8 | < 0.001 |
| ARCO stage I | 3.1 ± 2.7 | 0.8 ± 0.8 | 0.118 |
| ARCO stage II | 3.3 ± 2.8 | 1.5 ± 1.9 | 0.005 |
| ARCO stage III | 6.5 ± 1.1 | 3.3 ± 1.2 | 0.019 |
| BME unchanged | |||
| Total | 3.7 ± 2.2 | 3.5 ± 3.2 | 0.734 |
| ARCO stage I | 2.5 ± 1.5 | 0 ± 0 | 0.102 |
| ARCO stage II | 3.0 ± 1.9 | 3.1 ± 2.4 | 0.873 |
| ARCO stage III | 6.4 ± 0.4 | 7.6 ± 0.6 | 0.148 |
| BME progressed | |||
| Total | 5.5 | 1.5 | / |
| ARCO stage II | 5.5 | 1.5 | / |